Home About Us Research Services Financials / Press Releases Contact Us BIOQUAL STOCK TICKER BIOQUAL, Inc. Preclinical Testing CRO In The News Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants Alpha, Beta,Gamma and Delta Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization. Correlates of protection against SARS-CoV-2 in rhesus macaques Scientific publication to be published soon – Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice REGN-COV2 Antibodies Prevent and Treat SARS-CoV-2 Infection in Rhesus Macaques and Hamsters Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques BIOQUAL Announces Publication of an Investigational COVID-19 vaccine candidate that prevents severe clinical disease in animals Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters Potently neutralizing and protective human antibodies against SARS-CoV-2 Development of a potent Zika virus vaccine using self-amplifying messenger RNA BIOQUAL Announces Publication New England Journal Medicine. August, 10, 2020 Show more... Read More... BIOQUAL, Inc. is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in vivo and In vitro studies. About Us Research Services AIDS Read More Zika Read More Influenza Read More RSV Read More Malaria Read More Other Infectious Disease Areas Read More View All Services BIOQUAL’s laboratories are actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides and drug therapies. In vitro services are available. These services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. About Us BIOQUAL, Inc. Partnering with government, academic, and commercial organizations to provide innovative research support for improved global health Your Full Name Phone Number Email Address Message  240-404-7654 800-208-3149  info@bioqual.com  BIOQUAL, Inc. 9600 Medical Center Drive Suite 101 Rockville, MD 20850-3336 Copyright © 2021, BIOQUAL, Inc. All Rights Reserved. Website Design by Studio98